Wall Street brokerages expect that Natus Medical Inc (NASDAQ:BABY) will post $122.85 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Natus Medical’s earnings. The highest sales estimate is $123.00 million and the lowest is $122.70 million. Natus Medical reported sales of $130.65 million in the same quarter last year, which suggests a negative year-over-year growth rate of 6%. The firm is expected to report its next earnings results after the market closes on Thursday, July 25th.

On average, analysts expect that Natus Medical will report full-year sales of $495.95 million for the current year, with estimates ranging from $495.30 million to $496.60 million. For the next fiscal year, analysts anticipate that the company will report sales of $508.35 million, with estimates ranging from $507.40 million to $509.30 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Natus Medical.

Natus Medical (NASDAQ:BABY) last announced its earnings results on Thursday, April 25th. The medical equipment provider reported $0.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.03. The company had revenue of $114.80 million during the quarter, compared to the consensus estimate of $113.30 million. Natus Medical had a negative net margin of 8.62% and a positive return on equity of 10.75%. Natus Medical’s revenue was down 10.7% compared to the same quarter last year. During the same period last year, the firm earned $0.24 earnings per share.

BABY has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, June 26th. TheStreet cut shares of Trinity Industries from a “b” rating to a “c” rating in a report on Thursday, April 25th. BidaskClub cut shares of Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, June 1st. Finally, ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $36.00.

Shares of NASDAQ BABY traded up $0.06 during midday trading on Friday, reaching $25.88. The company had a trading volume of 126,900 shares, compared to its average volume of 297,883. The company’s 50-day moving average is $25.17. The company has a market cap of $879.39 million, a PE ratio of 18.31 and a beta of 0.57. Natus Medical has a 1 year low of $23.53 and a 1 year high of $37.90. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.18 and a current ratio of 1.70.

In related news, VP Austin Francis Noll III sold 14,250 shares of the firm’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $26.43, for a total transaction of $376,627.50. Following the sale, the vice president now owns 99,443 shares in the company, valued at $2,628,278.49. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Ken Ludlum sold 4,250 shares of the firm’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $24.41, for a total transaction of $103,742.50. Following the sale, the director now owns 46,192 shares in the company, valued at approximately $1,127,546.72. The disclosure for this sale can be found here. In the last three months, insiders have sold 48,515 shares of company stock valued at $1,264,239. 1.65% of the stock is currently owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Royce & Associates LP boosted its position in Natus Medical by 55.4% during the first quarter. Royce & Associates LP now owns 1,100 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 392 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Natus Medical during the first quarter worth about $38,000. NumerixS Investment Technologies Inc acquired a new position in Natus Medical during the first quarter worth about $114,000. Piedmont Investment Advisors Inc. boosted its position in Natus Medical by 4.8% during the first quarter. Piedmont Investment Advisors Inc. now owns 8,406 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 387 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan acquired a new position in Natus Medical during the fourth quarter worth about $329,000. Institutional investors own 91.56% of the company’s stock.

About Natus Medical

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Recommended Story: Municipal Bonds

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.